Product
XPro1595
Aliases
DN-TNF, INB03/XPro™, XENP1595
3 clinical trials
10 indications
Indication
Alzheimer's diseaseIndication
DementiaIndication
Brain DiseasesIndication
Central Nervous System DiseasesIndication
Nervous System DiseasesIndication
TauopathyIndication
Neurodegenerative DiseasesIndication
Neurocognitive DisordersIndication
Mental DisordersIndication
Mild Cognitive ImpairmentClinical trial
Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Alzheimer's Disease and Biomarkers of Inflammation.Status: Completed, Estimated PCD: 2021-06-30
Clinical trial
An Open Label Extension of XPro1595 in Patients With Alzheimer's Disease That Have Completed a Phase 1 or Phase 2 Study With XPro1595Status: Recruiting, Estimated PCD: 2026-05-04
Clinical trial
A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Mild Cognitive Impairment (MCI) With Biomarkers of InflammationStatus: Withdrawn, Estimated PCD: 2023-10-26